Bioage Labs, Inc.(BIOA) - 2025 Q3 - Quarterly Results

Exhibit 99.1 BioAge Labs Reports Third Quarter 2025 Financial Results and Provides Business Updates First participant dosed in Phase 1 trial of BGE-102, oral CNS-penetrant NLRP3 inhibitor, with initial SAD data expected by year-end Continued advancement of oral and parenteral APJ agonist programs targeting 2026 IND submissions Research and development expenses were $18.5 million for the quarter ended September 30, 2025, compared to $20.0 million for the same period in 2024. The $1.5 million decrease in rese ...